Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
bivirkning af dopaminergt lægemiddel, der anvendes ved parkinsonisme |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
2 |
Levodopa adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
bivirkning af co-beneldopa |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Apomorphine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Lysuride adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Pergolide adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Bromocriptine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Decarboxylase inhibitor adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
allergi over for lægemiddelgrupper med primær effekt på centralnervesystemet |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
allergi over for dopaminergt lægemiddel, der anvendes ved parkinsonisme |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Allergy to levodopa |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
allergi over for co-beneldopa |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Allergy to apomorphine |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Allergy to lisuride (finding) |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Allergy to pergolide (finding) |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Allergy to bromocriptine (finding) |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
allergi over for decarboxylasehæmmer |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
overdosis af lægemiddelgrupper med primær effekt på centralnervesystemet |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
1 |
overdosis af dopaminergt lægemiddel, der anvendes ved parkinsonisme |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
2 |
Levodopa overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Accidental levodopa overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Intentional levodopa overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
overdosis af levodopa, uvist med hvilken hensigt |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Lysuride overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Accidental lysuride overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Intentional lysuride overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
overdosis af lysurid, uvist med hvilken hensigt |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Bromocriptine overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Accidental bromocriptine overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Intentional bromocriptine overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
overdosis af bromocriptin, uvist med hvilken hensigt |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Overdose of anticonvulsant drug |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Vigabatrin overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Accidental vigabatrin overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Intentional vigabatrin overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
overdosis af vigabatrin, uvist med hvilken hensigt |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Decarboxylase inhibitor overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Psychostimulant overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
overdosis af ecstasy |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
tilsigtet overdosis af ecstasy |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
overdosis af ecstasy, uvist med hvilken hensigt |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Overdose of cocaine |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Accidental overdose by cocaine |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Intentional overdose by cocaine |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
overdosis af cocain, uvist med hvilken hensigt |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Overdose of crack cocaine (disorder) |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Accidental overdose by crack cocaine |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Intentional overdose by crack cocaine |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
overdosis af crack-cocain, uvist med hvilken hensigt |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Caffeine overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Accidental caffeine overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Intentional caffeine overdose |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
overdosis af koffein, uvist med hvilken hensigt |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Sedativ, hypnotisk OG/ELLER anxiolytisk induceret, persisterende amnetisk sygdom |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Sedative, hypnotic AND/OR anxiolytic-related disorder |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Magnesium sulfate powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
magnesiumsulfat 4 g/10 ml mikstur |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Magnesium sulfate BP crystals |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Drugs used in nausea and vertigo |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Drugs for the control of epilepsy |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Product containing vigabatrin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Vigabatrin 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Product containing precisely vigabatrin 500 milligram/1 sachet powder for conventional release oral solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Drugs used in status epilepticus |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Levodopa 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Levodopa with benserazide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Product containing precisely benserazide 12.5 milligram and levodopa 50 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Benserazide 25 mg and levodopa 100 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Product containing precisely benserazide 50 milligram and levodopa 200 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
co-beneldopa 12,5 mg/50 mg dispergibel tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
co-beneldopa kapsel med modificeret udløsning a 25 mg/100 mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
co-beneldopa 25 mg/100 mg dispergibel tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Bromocriptine [parkinsons] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Parlodel starter |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
lysuridmaleat 200 µg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
pergolid 50 µg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
pergolid 250 µg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
pergolid 1 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
pergolid 50 µg tablet og pergolid startpakning 250 µg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
apomorphinhydrochlorid 10 mg/ml injektionsvæske, opløsning, ampul a 2 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
apomorphinhydrochlorid 10 mg/ml injektionsvæske, opløsning, ampul a 5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
apomorphinhydrochlorid 30 mg/3 ml fyldt pen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Product containing precisely ropinirole (as ropinirole hydrochloride) 250 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Ropinirole (as ropinirole hydrochloride) 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Ropinirole (as ropinirole hydrochloride) 2 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Product containing precisely ropinirole (as ropinirole hydrochloride) 5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Cabergoline [parkinsons] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Cabergoline 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Cabergoline 2 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Cabergoline 4 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
pramipexol 88 µg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
pramipexol 180 µg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
pramipexol 700 µg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Biperiden hydrochloride 2 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Cerebral vessel spasmolytic |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Drugs used in substance dependence |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Drugs used for the treatment of motor neurone disease |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Product containing centrally acting acetylcholinesterase inhibitor (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Donepezil hydrochloride 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Donepezil hydrochloride 10 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
Product containing rivastigmine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|